IPO - Profile


We are a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that we believe has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. In the organ transplant setting, which is our initial focus, we believe our proprietary therapeutic approach, which we call Facilitated Allo-HSCT Therapy, could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$17.00 8,800,000 Positive High 33.38%

Offering Team

  • Legal counsel
  • Goodwin Procter LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 06 May, 2021

Offer 07 May, 2021

Look Ahead

Lock Up Expiry Nov 07, 2021

IPO Terms

Offer Price $17.00
Offer Size 8M

Market Sentiments

Stock Price